File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment of hepatitis C in kidney transplant recipients with interferon alpha-2b plus ribavirin

TitleTreatment of hepatitis C in kidney transplant recipients with interferon alpha-2b plus ribavirin
Authors
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
The 2003 World Congress of Nephrology, Berlin, Germany, 8-12 June 2003. In Nephrology Dialysis Transplantation, 2003, v. 18 n. suppl. 4, p. 381, abstract no. T316 How to Cite?
AbstractLimited data is available for the treatment of hepatitis C virus (HCV) infection in renal allograft recipients, in whom interferon therapy is generally regarded as contraindicated due to potential risks of acute rejection or graft dysfunction. We treated 4 patients who acquired acute hepatitis C in the perioperative period of kidney transplantation. All four patients, who were not HCV carriers before renal transplantation, developed acute transaminitis with negative anti-HCV serology, but positive circulating HCV RNA detectable by PCR. All patients were on cyclosporin-based immunosuppressive protocol. They received interferon alpha-2b (3 MU s.c. thrice weekly) and ribavirin (800-1200 mg p.o. daily according to body weight and hemoglobin levels) treatment. As shown in Table 1, three patients had complete remission with normalization of serum alanine aminotransferase (ALT) level within 4-12 weeks of therapy, and disappearance of serum HCV RNA at 24 and 48 weeks of starting therapy. Two of them had persistently undetectable HCV RNA at 24 weeks after cessation of therapy, while one had just completed the 48-week treatment at the time of writing. The non-responder, in whom treatment was stopped after 24 weeks due to persistent HCV-viremia, was infected with HCV gentotype 1b, which is known to be associated with a less favorable treatment response. All patients had stable renal allograft function throughout the course of treatment. Ribavirin-induced hemolysis, which was dose-dependent, was the most common side-effect. We conclude that combination interferon/ribavirin therapy can be a valid therapeutic option in renal transplant recipients with hepatitis C, but the decision on treatment should take into consideration the severity, progression, and prognosis of the hepatitis, the potential efficacy based on the HCV genotype, and the risk of inducing allograft dysfunction.
DescriptionSession B. Clinical Nephrology - B7. Hepatitis in glomerular disease, dialysis and transplant patients
Persistent Identifierhttp://hdl.handle.net/10722/101715
ISSN
2015 Impact Factor: 4.085
2015 SCImago Journal Rankings: 1.780

 

DC FieldValueLanguage
dc.contributor.authorTang, SCW-
dc.contributor.authorHo, EYW-
dc.contributor.authorCheng, IKP-
dc.contributor.authorKuok, UI-
dc.contributor.authorLeung, VKS-
dc.contributor.authorTang, AWC-
dc.contributor.authorKung, NNS-
dc.contributor.authorLai, KN-
dc.contributor.authorChan, DTM-
dc.date.accessioned2010-09-25T20:00:55Z-
dc.date.available2010-09-25T20:00:55Z-
dc.date.issued2003-
dc.identifier.citationThe 2003 World Congress of Nephrology, Berlin, Germany, 8-12 June 2003. In Nephrology Dialysis Transplantation, 2003, v. 18 n. suppl. 4, p. 381, abstract no. T316-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/101715-
dc.descriptionSession B. Clinical Nephrology - B7. Hepatitis in glomerular disease, dialysis and transplant patients-
dc.description.abstractLimited data is available for the treatment of hepatitis C virus (HCV) infection in renal allograft recipients, in whom interferon therapy is generally regarded as contraindicated due to potential risks of acute rejection or graft dysfunction. We treated 4 patients who acquired acute hepatitis C in the perioperative period of kidney transplantation. All four patients, who were not HCV carriers before renal transplantation, developed acute transaminitis with negative anti-HCV serology, but positive circulating HCV RNA detectable by PCR. All patients were on cyclosporin-based immunosuppressive protocol. They received interferon alpha-2b (3 MU s.c. thrice weekly) and ribavirin (800-1200 mg p.o. daily according to body weight and hemoglobin levels) treatment. As shown in Table 1, three patients had complete remission with normalization of serum alanine aminotransferase (ALT) level within 4-12 weeks of therapy, and disappearance of serum HCV RNA at 24 and 48 weeks of starting therapy. Two of them had persistently undetectable HCV RNA at 24 weeks after cessation of therapy, while one had just completed the 48-week treatment at the time of writing. The non-responder, in whom treatment was stopped after 24 weeks due to persistent HCV-viremia, was infected with HCV gentotype 1b, which is known to be associated with a less favorable treatment response. All patients had stable renal allograft function throughout the course of treatment. Ribavirin-induced hemolysis, which was dose-dependent, was the most common side-effect. We conclude that combination interferon/ribavirin therapy can be a valid therapeutic option in renal transplant recipients with hepatitis C, but the decision on treatment should take into consideration the severity, progression, and prognosis of the hepatitis, the potential efficacy based on the HCV genotype, and the risk of inducing allograft dysfunction.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.titleTreatment of hepatitis C in kidney transplant recipients with interferon alpha-2b plus ribavirin-
dc.typeConference_Paper-
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0931-0509&volume=18&issue=S4&spage=381&epage=&date=2003&atitle=Treatment+of+hepatitis+C+in+kidney+transplant+recipients+with+interferon+alpha-2b+plus+ribavirin.en_HK
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.emailHo, EYW: yeewaho@hkucc.hku.hk-
dc.identifier.emailCheng, IKP: hrmekpc@hkucc.hku.hk-
dc.identifier.emailLai, KN: knlai@hku.hk-
dc.identifier.emailChan, DTM: dtmchan@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.identifier.authorityLai, KN=rp00324-
dc.identifier.authorityChan, DTM=rp00394-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1093/oxfordjournals.ndt.a004623-
dc.identifier.hkuros95996-
dc.identifier.volume18-
dc.identifier.issuesuppl. 4-
dc.identifier.spage381, abstract no. T316-
dc.identifier.epage381, abstract no. T316-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats